Comparative phenotypic analysis of myeloma cell lines and lymphoblastoid cell lines
| . | CD19 . | CD20 . | CD38 . | CD138 . | CD40 . | CD70 . | κ . | λ . | HLA . |
|---|---|---|---|---|---|---|---|---|---|
| HMCL | |||||||||
| XG-1 | 1.0 | 0.9 | 80.3 | 75.0 | 1.1 | 1.3 | 3.2 | 0.8 | A2 A29 B40 B44 |
| XG-6 | 1.7 | 1.1 | 1.1 | 357.3 | 7.6 | 1.2 | 0.9 | 43.0 | A2 A2 B15 B37 |
| XG-7 | 1.1 | 0.9 | 65.0 | 30.7 | 1.1 | 89.0 | 11.8 | 1.0 | A2 A24 B7 B40 |
| XG-13 | 0.8 | 0.9 | 38.9 | 110.5 | 9.5 | 6.2 | 0.8 | 36.1 | A32 A68 B8 B40 |
| XG-14 | 1.0 | 0.9 | 134.2 | 107.8 | 9.2 | 21.2 | 50.2 | 0.9 | A2 A26 B38 B51 |
| XG-16 | 1.0 | 1.1 | 21.6 | 178.1 | 5.3 | 15.4 | 27.4 | 1.1 | A2 A29 B40 B49 |
| Mean ± SD | 1.1 ± 0.3 | 0.9 ± 0.1 | 56.8 ± 47.4 | 143.2 ± 115.4 | 5.63 ± 3.8 | 22.3 ± 33.5 | |||
| LCL | |||||||||
| EBV-1 | 45.0 | 91.0 | 6.5 | 9.0 | 46.6 | 150.8 | 80.9 | 2.3 | A2 A29 B40 B44 |
| EBV-13 | 33.3 | 55.7 | 33.8 | 1.2 | 16.3 | 64.5 | 240.5 | 3.1 | A32 A68 B8 B40 |
| EBV-14 | 32.6 | 149.0 | 61.1 | 23.1 | 40.8 | 53.6 | 71.5 | 26.4 | A2 A26 B38 B51 |
| EBV-16 | 18.6 | 53.0 | 2.2 | 17.1 | 23.9 | 71.9 | 132.6 | 89.5 | A2 A29 B40 B49 |
| Mean ± SD | 32.4 ± 10.8 | 87.2 ± 44.7 | 25.9 ± 27.3 | 12.6 ± 9.5 | 31.9 ± 14.2 | 85.2 ± 44.4 |
| . | CD19 . | CD20 . | CD38 . | CD138 . | CD40 . | CD70 . | κ . | λ . | HLA . |
|---|---|---|---|---|---|---|---|---|---|
| HMCL | |||||||||
| XG-1 | 1.0 | 0.9 | 80.3 | 75.0 | 1.1 | 1.3 | 3.2 | 0.8 | A2 A29 B40 B44 |
| XG-6 | 1.7 | 1.1 | 1.1 | 357.3 | 7.6 | 1.2 | 0.9 | 43.0 | A2 A2 B15 B37 |
| XG-7 | 1.1 | 0.9 | 65.0 | 30.7 | 1.1 | 89.0 | 11.8 | 1.0 | A2 A24 B7 B40 |
| XG-13 | 0.8 | 0.9 | 38.9 | 110.5 | 9.5 | 6.2 | 0.8 | 36.1 | A32 A68 B8 B40 |
| XG-14 | 1.0 | 0.9 | 134.2 | 107.8 | 9.2 | 21.2 | 50.2 | 0.9 | A2 A26 B38 B51 |
| XG-16 | 1.0 | 1.1 | 21.6 | 178.1 | 5.3 | 15.4 | 27.4 | 1.1 | A2 A29 B40 B49 |
| Mean ± SD | 1.1 ± 0.3 | 0.9 ± 0.1 | 56.8 ± 47.4 | 143.2 ± 115.4 | 5.63 ± 3.8 | 22.3 ± 33.5 | |||
| LCL | |||||||||
| EBV-1 | 45.0 | 91.0 | 6.5 | 9.0 | 46.6 | 150.8 | 80.9 | 2.3 | A2 A29 B40 B44 |
| EBV-13 | 33.3 | 55.7 | 33.8 | 1.2 | 16.3 | 64.5 | 240.5 | 3.1 | A32 A68 B8 B40 |
| EBV-14 | 32.6 | 149.0 | 61.1 | 23.1 | 40.8 | 53.6 | 71.5 | 26.4 | A2 A26 B38 B51 |
| EBV-16 | 18.6 | 53.0 | 2.2 | 17.1 | 23.9 | 71.9 | 132.6 | 89.5 | A2 A29 B40 B49 |
| Mean ± SD | 32.4 ± 10.8 | 87.2 ± 44.7 | 25.9 ± 27.3 | 12.6 ± 9.5 | 31.9 ± 14.2 | 85.2 ± 44.4 |
Flow cytometry analysis of cell surface antigens and immunoglobulin light chains are expressed as ratios of the MFIs of labeling obtained with an antigen-specific antibody and an isotype-matched control antibody recognizing no human antigen. The specific antibody and control antibody were conjugated with the same fluorochrome or recognized by the same fluorochrome-conjugated second antibody. Because HMCLs did not express surface Ig, cells were permeabilized with saponin before labeling with anti–κ or –λ human Ig light chains to detect cytoplasmic Ig. HLA class I typing demonstrates that the HMCLs and the corresponding LCLs are derived from the same patient.
HMCL indicates human myeloma cell line; LCL, lymphoblastoid cell line; EBV, Epstein-Barr virus; MFI, mean fluorescence intensity; Ig, immunoglobulin.